Stock Alert: Coherent Touches New High; Receives Buyout Proposal From MKS Instruments

By RTTNews Staff Writer   ✉   | Published:

Shares of laser manufacturer, Coherent, Inc. (COHR) are rising more than 15% Monday morning after the company said it has received an unsolicited buyout proposal from MKS Instruments.

According to the terms of the proposal from MKS, each common stock of Coherent would be exchanged for $115.00 in cash and 0.7473 of a share of MKS common stock.

On January 19, 2021, Coherent had announced its merger agreement with Lumentum Holdings Inc. As per the deal, each share of Coherent common stock would be exchanged for $100 in cash and 1.1851 shares of Lumentum common stock.

Coherent is planning to engage in discussions with MKS to gauge the benefits and risks compared to its proposed transaction with Lumentum.

"Notwithstanding its receipt of MKS' proposal and pending discussions between Coherent and MKS, Coherent's board of directors continues to recommend Coherent's merger agreement with Lumentum to its stockholders," the company said.

COHR touched a new high of $227.18 this morning before slipping to $222.51 currently.

For comments and feedback contact: editorial@rttnews.com

Business News

Next Story
Editors Pick
Amazon Workers In Alabama To Start Mail Ballots For Unionization Vote
Amazon warehouse workers in Alabama are starting their mail-in voting on unionization Monday after the National Labor Relations Board or NLRB rejected the company's request for a delay in election. The regulator will mail ballots to around 6,000 workers at the warehouse starting Monday to decide whether to unionize, and the ballots must be returned by March 29.
FDA OKs Bristol-Myers Squibb's Breyanzi To Treat Large-B-Cell Lymphoma
The U.S. Food and Drug Administration approved a new treatment for adult patients with certain types of large B-cell lymphoma (LBCL) who have not responded to, or who have relapsed after, at least two other types of systemic treatment. Bristol-Myers Squibb's Breyanzi (lisocabtagene maraleucel) is the third gene therapy to be approved by the FDA for Large-B-Cell Lymphoma.
AstraZeneca Vaccine Rollout Halted In South Africa
South Africa has halted the rollout of AstraZeneca- Oxford vaccine against Covid-19 after a study showed the vaccine provided minimal protection against a new variant. South African Health Minister Zweli Mkhize, while speaking at a news conference on Sunday, said there is a temporary hold as the government waits for further advice on how to proceed with the AstraZeneca- Oxford vaccine...